期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
Immunogenicity of the Spike Glycoprotein of Bat SARS-like Coronavirus 被引量:1
1
作者 Yu-xuan HOU Cheng PENG +3 位作者 Zheng-gang HAN Peng ZHOU Ji-guo CHEN Zheng-li SHI 《Virologica Sinica》 SCIE CAS CSCD 2010年第1期36-44,共9页
A group of SARS-like coronaviruses(SL-CoV)have been identified in horseshoe bats.Despite SL-CoVs and SARS-CoV share identical genome structure and high-level sequence similarity,SL-CoV does not bind to the same cellul... A group of SARS-like coronaviruses(SL-CoV)have been identified in horseshoe bats.Despite SL-CoVs and SARS-CoV share identical genome structure and high-level sequence similarity,SL-CoV does not bind to the same cellular receptor as for SARS-CoV and the N-terminus of the S proteins only share 64%amino acid identity,suggesting there are fundamental differences between these two groups of coronaviruses.To gain insight into the basis of this difference,we established a recombinant adenovirus system expressing the S protein from SL-CoV(rAd-Rp3-S)to investigate its immune characterization.Our results showed that immunized mice generated strong humoral immune responses against the SL-CoV S protein.Moreover,a strong cellular immune response demonstrated by elevated IFN-γand IL-6 levels was also observed in these mice.However,the induced antibody from these mice had weaker cross-reaction with the SARS-CoV S protein,and did not neutralize HIV pseudotyped with SARS-CoV S protein.These results demonstrated that the immunogenicity of the SL-CoV S protein is distinct from that of SARS-CoV,which may cause the immunological differences between human SARS-CoV and bat SL-CoV.Furthermore,the recombinant virus could serve as a potential vaccine candidate against bat SL-CoV infection. 展开更多
关键词 SARS coronavirus (SARS-CoV) SARS-like coronavirus (sl-cov) Spike glycoprotein Humoral immune response Cellular immune response
下载PDF
蝙蝠SARS样冠状病毒WIV1利用小鼠ACE2受体研究 被引量:1
2
作者 王琼 李丹 +3 位作者 李金燕 胡冰杰 邱烨 葛行义 《激光生物学报》 CAS 2020年第2期120-127,共8页
严重急性呼吸综合征冠状病毒(SARS-CoV)是一种感染人类的高致病性病毒,由蝙蝠SARS样冠状病毒(SL-CoV)演化而来。血管紧张素转换酶2(ACE2)是SARS-CoV受体,影响病毒宿主范围、致病性和种间传播。先前研究表明,SARS-CoV和一些SL-CoV株(如WI... 严重急性呼吸综合征冠状病毒(SARS-CoV)是一种感染人类的高致病性病毒,由蝙蝠SARS样冠状病毒(SL-CoV)演化而来。血管紧张素转换酶2(ACE2)是SARS-CoV受体,影响病毒宿主范围、致病性和种间传播。先前研究表明,SARS-CoV和一些SL-CoV株(如WIV1)可以有效利用人、果子狸、蝙蝠ACE2入侵细胞,而SARS-CoV可以低效利用小鼠ACE2。啮齿动物种类多,分布广,包括多种重要的试验动物模型,不过SL-CoV利用啮齿动物ACE2的研究较少。本研究通过假病毒感染试验,比较了SARS-CoV BJ01株和SL-CoV WIV1株利用人类、果子狸、蝙蝠、小鼠ACE2及其突变体进入细胞的效率,并利用蛋白结合试验比较了BJ01和WIV1受体结合结构域(RBD)结合不同ACE2及其突变体的能力。结果显示,SL-CoV WIV1可以有效利用小鼠ACE2进入细胞,且WIV1 RBD与小鼠ACE2结合效率与人和果子狸ACE2相同,强于蝙蝠ACE2;而不同物种ACE2的L440P突变能显著降低其与BJ01及WIV1的RBD结合的能力,抑制假病毒入侵。研究结果表明,小鼠ACE2是SL-CoV WIV1的功能受体,且ACE2的L440是影响病毒入侵的关键氨基酸位点。本研究有助于进一步了解SL-CoV的受体识别、跨种传播机制,对今后类似冠状病毒的防控具有重要意义。 展开更多
关键词 SARS冠状病毒 SARS样冠状病毒 血管紧张素转换酶2 受体结合区 ACE2-L440P
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部